Firmus has confirmed a strategic equity investment round of USD2 billion ($2.9 billion), led by follow-on participation from US investment company Coatue and chip giant Nvidia.
Biotech group CSL will undertake clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its patented Horizon 2 process.
Insurance broker Steadfast Group has extended its due diligence period granted to joint suitors Amwins Group and Dragoneer Investment Group, after the US-based pair re-confirmed their intention to proceed with their $7.7 billion takeover proposal.
The board of New Zealand tourism company Tourism Holdings has granted due diligence access to a consortium led by BGH Capital and the family interests of Luke and Karl Trouchet, following an all-cash offer of NZD3.10 ($2.55) per share announced in May.
The board of Atlas Arteria has reiterated its recommendation that shareholders should reject a $7 billion hostile takeover approach from IFM Investors, after its independent expert Kroll reconfirmed the validity of its valuation analysis.
Web Travel Group reported underlying group earnings of $148.4 million for FY27, up 23% compared to the prior year, but near the bottom of its guided range of $147 million to $155 million.
The Sydney firm will open a US-based research institute and seek to make five to 10 business investments in the untapped peri- and post-menopause healthcare market.
Guzman y Gomez will exit the US market, pleasing investors by shuttering all eight of its Chicago restaurants after a shaky rollout that had tested analysts’ patience.
